Anti-Aging Treatments & Technology: Complete Evidence Guide (2026)

How Does Science Rank Anti-Aging Treatments?

The modern framework for anti-aging treatments is built on the 12 hallmarks of aging, a taxonomy of the biological processes that deteriorate with age. These hallmarks, updated in 2023, include genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, disabled macroautophagy, chronic inflammation, and dysbiosis.

Every legitimate anti-aging treatment targets one or more of these hallmarks. The question for each treatment is: how strong is the evidence that it actually reverses or slows the targeted hallmark in humans? The answer ranges from "proven in controlled trials" (exercise, caloric restriction) to "theoretical only" (most gene therapies).

We organize treatments below by evidence tier, not by category. Tier 1 means controlled human trial data showing measurable aging reversal or delay. Tier 2 means strong mechanism data and preliminary human results. Tier 3 means promising preclinical data with limited or no human aging evidence. This ranking reflects the state of published science as of September 2026.

Which Anti-Aging Treatments Are Proven in Human Trials?

Structured exercise

Exercise is the single most evidence-backed anti-aging treatment available. It targets at least six of the 12 hallmarks simultaneously: mitochondrial dysfunction (improved oxidative capacity), deregulated nutrient sensing (AMPK activation, insulin sensitization), chronic inflammation (reduced CRP, IL-6), cellular senescence (clearance of senescent cells in muscle), stem cell exhaustion (satellite cell activation), and epigenetic alterations (measurable biological age reduction).

A 2025 review in Aging (Kawamura et al., Tohoku University) synthesized evidence showing that structured exercise induces "epigenomic rejuvenation" in blood and skeletal muscle. One cited study found sedentary middle-aged women reduced epigenetic age by two years after eight weeks of combined aerobic and strength training. A 2026 GeroScience pilot (De Meyer et al.) showed six months of cycling training reduced GrimAge by 7.44 months (p=0.012).

The critical distinction: casual physical activity (walking, gardening) offers health benefits but has weaker anti-aging effects than planned, progressive exercise programs that increase cardiovascular fitness and muscular strength. VO2 max, the gold standard for cardiorespiratory fitness, is more strongly associated with biological age than grip strength or body composition.

Diet and lifestyle protocols

A 2021 pilot RCT (Fitzgerald et al., Aging) tested an eight-week diet and lifestyle intervention and showed a 3.23-year decrease in Horvath clock age compared to controls (p=0.018). The protocol combined a specific diet (high in folate, betaine, polyphenols), probiotics, exercise, stress management, and sleep optimization. This is one of the largest epigenetic age reductions documented from a non-pharmaceutical intervention. See our complete reverse aging guide for the protocol details.

Caloric restriction and time-restricted eating

Caloric restriction (CR) is the oldest and most replicated lifespan-extending intervention in animal models. The CALERIE trial (Phase 2, 2-year human study) showed that 12% caloric restriction improved cardiometabolic biomarkers and reduced markers of biological aging compared to ad libitum eating. Time-restricted eating (confining food to an 8-10 hour window) activates autophagy and improves insulin sensitivity, though its independent effect on epigenetic aging clocks in humans has not been established.

Which Treatments Have Strong Mechanisms but Limited Human Data?

NAD+ restoration (NMN and NR)

NAD+ (nicotinamide adenine dinucleotide) declines roughly 50% between ages 30 and 70, impairing sirtuin activity, DNA repair, and mitochondrial energy production. NAD+ decline is recognized as one of the 12 hallmarks of aging. NMN (nicotinamide mononucleotide) is the direct precursor to NAD+.

The evidence: a January 2026 trial in Nature Metabolism (Christen et al., 65 adults) confirmed that both NMN and NR double whole-blood NAD+ in 14 days at 1,000 mg/day. A 2026 meta-analysis pooling 12 RCTs (513 participants) confirmed reliable NAD+ elevation. A 12-week trial (Morifuji et al., 2024) showed improved walking speed and sleep quality at 250 mg/day. Safety data across published trials shows no serious adverse events at doses up to 1,250 mg/day.

What makes NMN stand out among anti-aging treatments: it is oral, OTC, well-tolerated, backed by 30+ human trials, and targets an upstream aging mechanism that influences multiple downstream pathways. The open question is whether NAD+ restoration translates to measurable epigenetic age reversal, with trials underway.

For product selection, see our best NMN supplements guide. For how NMN compares to NR and niacin, see our NAD+ supplement guide. For dosing, see our NMN dosage review.

Rapamycin (mTOR inhibition)

Rapamycin is the most reliable lifespan extender across species (worms, flies, mice, with consistent 10-25% median lifespan extension). It works by inhibiting mTOR, the nutrient-sensing pathway that shifts cells from growth to maintenance. The PEARL trial published 48-week results in 2025 showing acceptable safety, improved lean tissue, and reduced pain in women taking 10 mg/week.

The trade-offs: rapamycin requires a prescription, causes mouth sores in many users, may impair wound healing, and has potential immune-suppressive effects (though the low-dose, intermittent protocols used in longevity differ from the high-dose chronic regimens used in transplant medicine). The Dog Aging Project is testing rapamycin in companion dogs, with results expected to inform human longevity use.

GLP-1 receptor agonists

Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) were developed for diabetes and obesity but show cardiovascular, kidney, and liver benefits that may extend beyond weight loss. The SELECT trial showed semaglutide reduced cardiovascular events by 20% in non-diabetic obese adults. Whether these drugs slow biological aging independent of metabolic improvement is under investigation, but the breadth of their systemic effects has prompted several aging researchers to add them to longevity protocols.

Core supplements with aging-relevant evidence

Beyond NMN, several supplements have controlled human data relevant to aging hallmarks — we rank them in our guide to the best anti-aging supplements. Creatine (3-5 g/day) preserves muscle mass and has emerging cognitive benefits in older adults, addressing sarcopenia (a key aging phenotype). Vitamin D3 (2,000-5,000 IU/day) deficiency correlates with accelerated biological aging; supplementation in deficient populations improves immune function and bone density. Omega-3 fatty acids (2 g EPA+DHA/day) reduce chronic inflammation (CRP, IL-6), addressing the "inflammaging" hallmark. Taurine drew attention after a 2023 Science paper showed taurine-deficient mice aged faster and taurine supplementation extended lifespan, though human longevity trials are pending.

Which Anti-Aging Technologies Are Still Experimental?

Senolytics

Senescent cells accumulate with age and secrete inflammatory factors (SASP) that damage healthy tissue. Senolytic drugs aim to selectively clear these "zombie cells." The combination of dasatinib plus quercetin (D+Q) has shown results in early human trials: the SToMP-AD Phase 1 trial (2023) demonstrated brain penetrance and reduced inflammatory markers in Alzheimer's patients. The STAMINA pilot (2025) tested D+Q for cognition and mobility. Unity Biotechnology's senolytic candidate failed two Phase 2 trials, highlighting the gap between animal and human results.

For consumers: quercetin alone is not a senolytic. The D+Q combination requires prescription dasatinib. Fisetin, a natural senolytic candidate, is in human trials. High-intensity exercise has been shown to reduce senescent cell markers in muscle tissue, making it the most accessible "senolytic" strategy.

Partial epigenetic reprogramming

The transient expression of Yamanaka factors (OSK) to reset age-related epigenetic marks has the highest theoretical ceiling among all anti-aging technologies. In mice, AAV-delivered OSK extended remaining lifespan by 109% (Macip et al., 2024). Life Biosciences received FDA IND clearance in 2026 for ER-100, the first human reprogramming trial (targeting optic neuropathies). Altos Labs ($3B), Retro Biosciences, and NewLimit are developing related approaches. For the full analysis, see our longevity research news.

Anti-aging peptides

Peptides like BPC-157, GHK-Cu, Epithalon, and Thymosin Alpha-1 target specific aging mechanisms (tissue repair, telomere maintenance, immune restoration, skin remodeling). The evidence profile is thin: BPC-157 has zero human RCTs. GHK-Cu works topically for skin but systemic effects are unproven. Thymosin Alpha-1 has the strongest clinical record (approved in 35+ countries for immune indications). Most require injection and sit in an evolving FDA regulatory gray zone following the 2023 Category 2 restrictions and partial 2026 reversal.

Senolytic CAR-T cell therapy

Proposed in 2020 and advancing in preclinical models, engineered CAR-T cells that target senescent cell surface markers could offer more precise senescent cell clearance than small-molecule senolytics. This is a research-stage technology with no human aging trials.

AI-driven drug discovery for aging

Machine learning is accelerating the identification of geroprotective compounds. A 2025 Scripps Research study demonstrated a 70% success rate in using AI to identify life-extending compounds in C. elegans. Insilico Medicine's AI-discovered drug (for idiopathic pulmonary fibrosis) reached Phase 2 trials. The technology is a tool for finding new anti-aging compounds, not a treatment itself, but it is compressing timelines that previously took decades.

Do Topical Anti-Aging Treatments Slow Real Aging?

While this guide focuses on systemic aging, topical treatments for skin aging have their own evidence base. These are cosmetic interventions that do not affect biological aging at the cellular or epigenetic level.

Retinoids (tretinoin, adapalene, retinol) are the most evidence-backed topical anti-aging treatment. Prescription tretinoin increases collagen production, accelerates cell turnover, and reduces fine lines. Dozens of controlled trials support its efficacy for photoaging. OTC retinol is weaker but still active.

Sunscreen prevents UV-induced photoaging, which accounts for up to 80% of visible facial aging. Daily broad-spectrum SPF 30+ is the single most impactful cosmetic anti-aging intervention. A landmark Australian RCT showed daily sunscreen use produced measurably younger-looking skin over 4.5 years.

Oral collagen peptides have 20+ RCTs showing improvements in skin hydration and elasticity, though a 2025 high-quality meta-analysis found the benefits weakened when pharmaceutical-company-funded studies were excluded.

Topical GHK-Cu has multiple controlled human studies for skin density and firmness. It is available OTC and is the most evidence-backed peptide for skin aging specifically.

LED therapy, microneedling, and platelet-rich plasma (PRP) have growing evidence for skin rejuvenation but limited standardization across studies. They are professional treatments, not consumer products.

None of these topical treatments addresses systemic aging hallmarks. For whole-body aging, the interventions described in Tiers 1-3 above are what the science targets.

How Do All Anti-Aging Treatments Compare?

The following comparison reflects published evidence as of September 2026. "Human aging data" means controlled trials using aging-specific endpoints (epigenetic clocks, functional decline, mortality).

Exercise. Hallmarks targeted: 6+. Human aging data: multiple trials showing epigenetic age reversal. Access: free. Cost: $0. Risk: very low. Best for: everyone, as the foundation layer.

NMN supplementation. Hallmarks targeted: NAD+ decline, mitochondrial dysfunction, sirtuin activity. Human data: 30+ trials, NAD+ doubling confirmed. Access: OTC. Cost: $30-60/month. Risk: very low (no serious adverse events in published trials). Best for: anyone seeking to restore NAD+ as part of a multi-pathway protocol. Product page.

Rapamycin. Hallmarks targeted: deregulated nutrient sensing (mTOR), autophagy. Human data: PEARL trial (48 weeks, safety + lean mass). Access: prescription. Cost: $50-200/month + physician. Risk: moderate (mouth sores, immune effects). Best for: physician-supervised longevity protocols.

Metformin. Hallmarks targeted: deregulated nutrient sensing (AMPK). Human data: TAME ongoing, DPP 21-year follow-up showed lifestyle beat metformin. Access: prescription. Cost: $4-10/month. Risk: GI distress, exercise blunting. Best for: diabetic/prediabetic populations. See our full metformin analysis.

Senolytics (D+Q). Hallmarks targeted: cellular senescence. Human data: Phase 1 signals (SToMP-AD, STAMINA). Access: physician-supervised. Cost: $100-300/course. Risk: unknown long-term. Best for: clinical trial participants.

Peptides. Hallmarks targeted: varies by peptide. Human aging data: zero RCTs for most. Access: evolving (compounding pharmacies). Cost: $50-300/month. Risk: unknown (thin safety data). Best for: physician-supervised, after foundational layers are solid. See our peptides comparison.

Epigenetic reprogramming. Hallmarks targeted: all (theoretically). Human data: first trial (ER-100) just cleared FDA. Access: clinical trials only. Cost: N/A. Risk: theoretical cancer risk. Best for: watching and waiting.

How Should You Build an Anti-Aging Protocol?

The most common mistake in anti-aging is jumping to advanced treatments while skipping the foundation. The evidence hierarchy suggests building in layers:

Layer 1 (do this first, non-negotiable): Exercise 150+ minutes/week cardiovascular + resistance training 2-3x/week. Sleep 7-8 hours consistently. Mediterranean-pattern diet. Sunscreen daily. These interventions have the largest evidence base and the lowest risk.

Layer 2 (add when Layer 1 is consistent): NMN 250-500 mg/day for NAD+ restoration. Creatine 3-5 g/day. Vitamin D3 2,000-5,000 IU/day. Omega-3 2g EPA+DHA/day. See our best NMN supplements and NAD+ supplement guide for product selection. These are OTC, evidence-based, and address specific aging hallmarks that lifestyle alone may not fully cover.

Layer 3 (physician-supervised): Rapamycin (low-dose weekly). Metformin (for appropriate metabolic profiles). GLP-1 agonists (for metabolic conditions). Peptide therapy (for specific clinical targets). Biological age testing (epigenetic clocks every 6-12 months) to track whether interventions are working.

Layer 4 (monitor for future availability): Partial epigenetic reprogramming. Senolytic combination therapies. Gene therapies targeting aging pathways. These represent the future of anti-aging medicine but are not yet consumer treatments.

For the complete breakdown of what works and what is speculation, see our how to reverse aging guide and longevity supplements ranking.

What Emerging Anti-Aging Technologies Should You Watch?

Biological age testing as a treatment feedback tool

Epigenetic clocks (GrimAge, DunedinPACE, PhenoAge) have moved from research tools to consumer products. Services like TruDiagnostic and Elysium offer at-home test kits for $200-500. The practical value is not a single snapshot but serial measurement: testing every 6-12 months lets you see whether your protocol is actually reducing biological age or just making you feel better.

DunedinPACE may be the most useful for tracking interventions because it measures the current rate of aging rather than cumulative biological age. A GrimAge score tells you how old your biology looks overall. DunedinPACE tells you how fast you are aging right now. If you start NMN, increase exercise, or change your diet, DunedinPACE can detect a slowdown in weeks to months rather than requiring years to see a shift in total biological age.

The limitation: these clocks are validated at a population level (they predict mortality and disease risk across thousands of people) but have meaningful measurement error at the individual level. A single test showing you are "3 years younger" than your chronological age is not precise enough to draw conclusions. The signal emerges from tracking changes over time, which is why serial testing matters more than any individual result.

Combination and sequential therapy

The frontier of anti-aging research is moving toward multi-pathway interventions rather than single compounds. A 2025 review in the International Journal of Molecular Sciences proposed that intermittent senolytic therapy followed by chronic metabolic modulation with NAD+ precursors or metformin may yield additive or synergistic benefits by addressing multiple aging hallmarks in a temporally coordinated manner.

The logic: clear senescent cells first (senolytics), then support the remaining healthy cells with NAD+ restoration (NMN) and metabolic optimization (exercise, caloric restriction mimetics). This sequential approach has not been tested in a human trial, but it reflects how longevity physicians are beginning to design protocols, layering interventions across different hallmarks rather than maximizing a single pathway.

David Sinclair's personal protocol (NMN + resveratrol + metformin + D3 + K2) is an informal version of multi-pathway targeting. The TRIIM trial (GH + DHEA + metformin) is a tested version. The longevity supplement stacking approach used by many biohackers follows the same principle, though usually without the physician oversight or biomarker tracking that makes it evidence-informed rather than speculative.

Genflow Biosciences SIRT6 gene therapy

SIRT6 is a sirtuin enzyme involved in DNA repair, telomere maintenance, and metabolic regulation. SIRT6 overexpression has extended lifespan in mice. Genflow Biosciences is developing an AAV-based SIRT6 gene therapy and has shown promising results in preclinical models. This is a gene-therapy approach to enhancing sirtuin activity directly, as opposed to the indirect approach of raising NAD+ (which fuels all seven sirtuins) through supplementation. The company is in early-stage development with no human trials published as of 2026.

Young plasma and parabiosis-inspired therapies

Heterochronic parabiosis experiments (connecting the circulatory systems of old and young mice) have shown that factors in young blood can rejuvenate old tissues. This led to interest in young plasma transfusions for anti-aging, though the first human trial (Ambrosia) was shut down by the FDA in 2019 for making unsubstantiated claims. Newer approaches focus on identifying specific circulating factors (GDF11, exosomes, specific proteins) rather than whole plasma. Elevian and Alkahest are developing targeted therapies based on parabiosis research. As of 2026, no young-blood-derived anti-aging therapy has demonstrated efficacy in a controlled human trial.

Which Anti-Aging Claims Have No Evidence?

The anti-aging market is flooded with products and claims that lack scientific support. Being explicit about what does not work is as important as identifying what does.

Most "anti-aging" skincare ingredients beyond retinoids and sunscreen have weak or no controlled trial evidence for measurable skin aging reversal. Products containing plant stem cells, exotic peptide blends, or "cellular renewal complexes" are primarily marketing constructs. The ingredients with actual controlled trial support for skin aging are retinoids, sunscreen, and (to a lesser degree) topical vitamin C, niacinamide, and GHK-Cu.

Oral hyaluronic acid supplements are marketed for skin hydration and joint health. A few small trials show modest skin hydration improvements, but the evidence is weaker and less consistent than for collagen peptides, which themselves have quality concerns in the literature.

NAD+ IV infusions are offered by longevity clinics at $250-1,000 per session with claims of immediate energy and anti-aging benefits. The 2026 Nature Metabolism trial showed that oral NMN and NR double NAD+ comparably to what IV protocols claim, at a fraction of the cost and without the need for clinical visits. See our NAD+ IV therapy analysis for the full comparison.

Unregulated "research peptides" purchased from gray-market vendors carry no quality assurance. Independent analyses have found samples that were mislabeled, contaminated, or under-dosed. Injecting unverified compounds bypasses every protective barrier the body has. If you use peptides, source them through licensed compounding pharmacies with a physician's prescription.

Telomere-lengthening supplements (astragalus extract / TA-65) are marketed with claims of activating telomerase. The human evidence consists of small, poorly controlled studies with modest or inconsistent results. Telomere length is one hallmark of aging, but targeting it in isolation, without addressing the other 11 hallmarks, has not produced meaningful clinical outcomes.

Hormone replacement for anti-aging in healthy adults (HGH, testosterone, DHEA as standalone anti-aging therapies) carries real risks (cancer risk from elevated IGF-1, cardiovascular risk from testosterone in some populations) that may outweigh speculative anti-aging benefits in people without diagnosed hormone deficiency. The TRIIM trial combined GH with DHEA and metformin under careful monitoring and showed results, but GH alone without metabolic counterbalancing is a different risk profile.

Frequently Asked Questions

What is the most effective anti-aging treatment?

Exercise. Controlled human trials show structured exercise programs reduce biological age on epigenetic clocks, improve every major aging biomarker, and are associated with lower all-cause mortality. No pharmaceutical or supplement intervention has matched exercise for breadth and strength of anti-aging evidence. If you add one thing, make it 150+ minutes per week of cardiovascular training plus resistance training 2-3 times per week. The De Meyer GeroScience trial showed this level of training reduces GrimAge by over 7 months in six months. Among supplements, NMN has the strongest clinical profile for addressing a core aging hallmark (NAD+ decline). See our best NMN supplements guide.

What anti-aging treatments actually work?

Treatments with controlled human trial evidence for aging-specific endpoints include exercise (epigenetic age reversal in multiple studies), diet-and-lifestyle protocols (Fitzgerald 2021: -3.23 years on Horvath clock), and the TRIIM trial (GH + DHEA + metformin: -2.5 years on GrimAge). NMN reliably restores NAD+, a core aging coenzyme, in 30+ trials. Topical retinoids and sunscreen are proven for skin aging specifically. Most other treatments (peptides, senolytics, reprogramming) are in early stages with limited or no human aging data.

Are anti-aging supplements worth it?

Some are, based on human evidence. NMN (doubles NAD+, clean safety profile, 30+ trials), creatine (muscle and cognitive preservation), vitamin D3 (immune and bone health), and omega-3 (anti-inflammatory) have controlled human data relevant to aging hallmarks. Most other anti-aging supplements have weaker evidence. The key: supplements work on top of lifestyle (exercise, sleep, diet), not as replacements for it. Start with exercise and sleep, then add NMN for NAD+ restoration, creatine for muscle and brain, and vitamin D3 for immune and bone health. This combination addresses four different aging hallmarks at a total cost under $100/month.

What is the latest anti-aging technology in 2026?

Partial epigenetic reprogramming is the most advanced new technology. Life Biosciences received FDA clearance for the first human trial (ER-100) in 2026. Senolytic CAR-T cell therapy, AI-driven geroprotective drug discovery, and combination aging pathway interventions are also advancing rapidly. For a full review of recent breakthroughs, see our longevity research news.

How much do anti-aging treatments cost?

Exercise: free. Sunscreen: $10-30/month. NMN supplementation: $30-60/month. Core supplements (D3 + omega-3 + creatine): $20-40/month. Prescription rapamycin: $50-200/month plus physician costs. Peptide therapy through compounding pharmacies: $50-300/month plus physician. Biological age testing: $200-500/test. The most effective interventions (exercise, sleep, diet) are the cheapest. The most expensive ones (peptides, reprogramming) have the weakest human evidence. The best value in the supplement category is NMN at $30-60/month, which addresses a core aging hallmark (NAD+ decline) with 30+ human trials behind it. The worst value is unregulated gray-market peptides, which combine high cost, injection risk, and thin evidence.

Sources

1. Kawamura T, Higuchi M, Radak Z, Taki Y. "Exercise as a geroprotector: focusing on epigenetic aging." Aging. 2025;17. DOI
2. De Meyer T, Stegen S, Rietzschel ER, et al. "Epigenetic age deceleration reflects exercise-induced cardiorespiratory fitness improvements." GeroScience. 2026. DOI
3. Christen S, Cuenoud B, et al. "The differential impact of three different NAD+ boosters." Nature Metabolism. 2026;8(1):62-73. PubMed
4. Fitzgerald KN, et al. "Potential reversal of epigenetic age using a diet and lifestyle intervention." Aging. 2021;13(7):9419-9432 (2024 correction: within-group figure revised; between-group -3.23y unchanged). PubMed
5. Moel M, et al. "Influence of rapamycin on safety and healthspan metrics: PEARL trial." Aging. 2025;17(4):908-936. PubMed
6. Salive ME, et al. "Lifestyle and metformin interventions and risk of multimorbidity: DPP 21-year follow-up." JAMA. 2026;336(7):577-586. PubMed
7. Gonzales MM, Orr ME, et al. "Senolytic therapy in mild Alzheimer's disease: SToMP-AD." Nature Medicine. 2023;29(10):2481-2488. PubMed
8. Macip CC, Davidsohn N, et al. "Gene therapy-mediated partial reprogramming extends lifespan in aged mice (+109%)." Cellular Reprogramming. 2024;26(1):24-32. PubMed
9. Singh P, Yadav VK, et al. "Taurine deficiency as a driver of aging." Science. 2023;380(6649):eabn9257. PubMed
10. "Insights into therapeutic strategies for aging and aging-associated diseases." Signal Transduction and Targeted Therapy (Nature). June 2026. Full text
11. "Rewinding the clock: emerging pharmacological strategies for human anti-aging therapy." Int J Mol Sci. 2025;26(19):9372. PMC
12. Yi L, Maier AB, et al. "NMN supplementation in healthy middle-aged adults." GeroScience. 2023;45(1):29-43. PubMed